SCHEMBL3479554

SCHEMBL3479554

CC(C)Oc1cccc(CN2CCC3(CC2)C(=O)NC(=O)N3c2cc(F)ccc2-c2ccc(S(=O)(=O)N(C)C)cc2)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.37
JAK1 P23458 2/20 0.37
NR1H2 P55055 1/20 0.36
MMP1 P03956 1/20 0.35
MMP9 P14780 1/20 0.35
MMP13 P45452 1/20 0.35
ADAM17 P78536 1/20 0.35
BACE1 P56817 3/20 0.35
CACNA1F O60840 1/20 0.35
CHRM2 P08172 1/20 0.35
ADRB1 P08588 1/20 0.35
DRD2 P14416 1/20 0.35
SLC6A2 P23975 1/20 0.35
ADRA1D P25100 1/20 0.35
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
ADRA1B P35368 1/20 0.35
OPRM1 P35372 1/20 0.35
DRD3 P35462 1/20 0.35
OPRD1 P41143 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3479427 0.95 NR1H2 (0.35) JAK2JAK1NR1H2MMP1MMP9
SCHEMBL13031015 0.93 JAK2 (0.36) JAK2JAK1NR1H2MMP1MMP9
SCHEMBL3479561 0.90 BACE1 (0.37) JAK2JAK1BACE1CACNA1FCHRM2
SCHEMBL3479470 0.89 JAK2 (0.35) JAK2JAK1NR1H2MMP1MMP9
SCHEMBL3479526 0.88 BACE1 (0.39) JAK2JAK1NR1H2MMP1MMP9
SCHEMBL3479560 0.88 MCHR1 (0.43) JAK2JAK1NR1H2BACE1DRD2
SCHEMBL3479471 0.87 BACE1 (0.34) BACE1CACNA1FCHRM2ADRB1DRD2
SCHEMBL3479638 0.86 JAK2 (0.35) JAK2JAK1NR1H2MMP1MMP9
SCHEMBL3479457 0.86 BACE1 (0.39) JAK2JAK1NR1H2MMP1MMP9
SCHEMBL592547 0.86 JAK2 (0.36) JAK2JAK1NR1H2MMP1MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US claimed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease MERCK & CO., INC. (US) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298342-A1 Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease BACE1, APP, PSEN1 JAK2 4818/4885JAK1 4835/4885NR1H2 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.